Home
/
AMICUS THERAPEUTICS, INC. (FOLD)
AMICUS THERAPEUTICS, INC. (FOLD) Technical Analysis
Updated: 2026-05-01 03:14 UTC · Last close: 14.49 (+0.00%) · Support: 14.26 · Resistance: 15.47
AMICUS THERAPEUTICS, INC. (FOLD) technical analysis page covering price structure, support and resistance, momentum conditions and a fundamentals snapshot from WOI Scanner.
⚠️ Risk Line
losing 14.26 would weaken the current structure.
Quick Read
From a roadmap perspective, the setup is boxed by support near 14.26 and resistance around 15.47.
🎯 Decision Map
From a roadmap perspective, the setup is boxed by support near 14.26 and resistance around 15.47. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
📊 Technical Summary
The latest close for AMICUS THERAPEUTICS, INC. (FOLD) came in at 14.49 (+0.00%). Price continues to hold above both the 50-day and 200-day moving averages, which keeps the broader trend structure constructive. 20-day momentum is positive at +0.56%, with price is trading in the upper part of its roughly 52-week range (5.64–14.49), while ATR14 volatility is relatively contained at roughly 0.11% of price. RSI(14) is 72.1, which reflects strong upside momentum, although the indicator is approaching stretched territory. MACD remains below its signal line, which shows that momentum confirmation is still limited. The MACD histogram remains negative, suggesting momentum is still on the softer side. Recent trading volume is running below its typical 20-day average, which suggests participation remains relatively muted. Near-term structure is defined by support at 14.26 and resistance at 15.47. A clean break above resistance would strengthen the chart, while a loss of support would put the current setup under pressure. Fundamentals snapshot: Revenue: 169.06M · Net income: 17.31M · EPS (basic): 0.06. The interactive chart adds overlays, pattern context and a fuller structure view for deeper review.
💼 Fundamentals Snapshot
Source: sec
Company
AMICUS THERAPEUTICS, INC.
Note: This is an algorithmic technical snapshot (not financial advice).